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TheNd-YAG laser has good tissue penetration and coagulation effects thus has become an
important weapon for photoresection of tracheobronchial obstructive lesions since 1980.
Treatment of benign lesions including benign tumors and scar tissues using the Nd-
YAG laser has good results. In the treatment ofmalignant tumors however, it has a lower
effectivity rate when compared to benign lesions. From July 1984 to September 1995, a
total of 65 patients were treated with Nd-YAG laser for tracheobronchial obstruction.
There were 32 (49%) malignant tumors and 33 (51%) benign lesions. 116 resections were
performed in 48 patients using the non-contact Nd-YAG laser (MBB, Medilas 2) before
1992. Thereafter, another 41 resections were performed in 17 cases using contact Nd-
YAG laser (SLT, CL-X). The overall effectivity rate was 60%. The effectivity rate for
benign lesions was 81.3% and 39.4% for malignant tumor. The effectivity rate between
non-contact and contact Nd-YAG laser was not significantly different.
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INTRODUCTION
The causes of tracheobronchial obstruction are divided
into two main groups as to the nature of the occluding
lesion. One is malignant neogrowths, primary as well
as metastatic tumors, or it may be benign, like scar tis-
sues, benign tumors, foreign body and others.
Tracheobronchial obstruction can be treated either
by surgery, radiotherapy, cryosurgery, electrocoagula-
tion, laser photoresection, photodynamic therapy or by
placement of tracheal stents for relief of obstruction.
Laser treatment for airway obstruction secondary to
malignant tumor is mainly palliative. CO2, Argon and
Nd-YAG laser are mediums for laser photoresection.
The most effective medium is Nd-YAG due to its
greater power density and deeper degree of tissue pen-
etration. Laser treatment may sometimes be used for
the curative treatment of small superficial lesions of
the tracheobronchial tree and also for low-grade
malignant tumors. Utilization of laser photoresection
for the palliative treatment of malignant tumors have
several advantages compared to other modalities of
treatment. Firstly, there is no systemic toxicity sec-
ondary to cumulation of doses as in radiotherapy.
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Furthermore, the procedure is well-tolerated by the
patient, attains adequate hemostasis and causes little
damage to surrounding tissues. CO2, Argon and Nd-
YAG laser photoresection can also be used for the
treatment of airway obstruction due to benign lesions.
As in cases of malignancy, the Nd-YAG laser is the
most effective. Generally speaking, there are better
results and lesser complications in cases of benign
lesion than in malignant tumor 1]. Scar tissues may
cause diaphragmatic or bottle-neck types of airway
obstruction. Treatment outcomes are better for the
diaphragmatic type than for the bottle-neck types [2].
Using laser photoresection for treatment of airway
obstruction poses some limitations. Lesions should be
intraluminal and should be within the accessible range
of the bronchoscope. Conditions such as upper lobe
bronchus obstruction and obstruction length more than
4 cm. makes the treatment technically difficult and
thus, have poor results. The complications of laser
photoresection are: massive bleeding, perforation of
bronchial wall, bronchial obstruction, smoke inhala-
tion and others such as cardiac arrest and arrhythmias.
A rigid or a flexible bronchoscope is generally
employed for laser photoresection. Advantages and
disadvantages for each type of bronchoscope is shown
in Table I. In general, rigid bronchoscope is used for
obstructions in the central airways associated with
ventilatory distress and the flexible bronchoscope is
used for distal small airways obstruction. Nd-YAG
laser for photoresection are of two types, contact and
non-contact. Contact Nd-YAG laser probes are made
of synthetic sapphire crystal which was available since
the early 1980s [3]. Contact Nd-YAG laser offers
several advantages including: greater precision in aim-
ing, lower power requirement, greater control of depth
penetration and more protection of the laser fiber from
soiling and deterioration. From 1984, the Nd-YAG
laser became a treatment option for tracheobronchial
obstruction at the Veteran General Hospital-Taipei.
We collected all cases of laser photoresection per-
formed at our institution over the past 10 years and
data were analyzed retrospectively.
The purposes of this study are: (1) to determine the
indications and utilities of Nd-YAG laser treatment,
(2) to evaluate the treatment results of different dis-
ease groups, (3) to compare results between contact
and non-contact Nd-YAG laser treatments and (4) to
evaluate the possible complications of Nd-YAG laser
treatment.
MATERIALS AND METHODS
From July 1984 to September 1995, there were 65
patients who received Nd-YAG laser treatment for
tracheobronchial obstruction. A total of 157 photore-
sections were performed. One hundred sixteen pho-
toresections for 48 patients were performed using the
non-contact Nd-YAG laser and 41 photoresections for
17 patients were performed using the contact Nd-YAG
laser. During treatment of these patients, we employed
the use of a flexible fiberoptic bronchoscope and per-
formed the treatment under local anaesthesia. Prior to
1992, we used non-contact type Nd-YAG laser (MBB,
Medilas 2), afterwhich, we changed to the use of con-
tact type Nd-YAG laser (SLT, CL-X).
The diagnoses of the study group are shown in
Table II. Benign lesions comprised 49%, mostly scar
tissues. Malignant tumor accounted for 51%, which
are most commonly situated in the bronchus.
TABLE Comparison between rigid and flexible bronchoscope in
laser photoresection
Rigid Flexible
General anaesthesia risk Yes No
Ease of manipulation No Yes
Bleeding control Good Poor
Fire risk No Yes
Resectability Good Poor
Airway control Good Poor
TABLE II Distribution of cases
Diagnosis No. %
Benign 32 49
Scar tissue 23
Tumor 7
Others 2
Malignant 33 51
Trachea 7
Bronchus 23
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RESULTS
The effectivity rates of laser treatment for different
diagnostic groups are shown in Table HI. The overall
effectivity rate for benign lesions is 81.3%, better than
for malignant tumor with only 39.4% (p < 0.005).
About halfofbenign cases were cured by laser treament
alone. As a whole, we had an effectivity rate of 60%.
The effectivity rate of laser treatment as to types of
lasers are shown in Table IV. The effectivity rate for
non-contact laser is 62.5% and 52.9% for contact
laser, showing no significant difference (p > 0.4). We
encountered only 3 cases of major complications
which included one case ofmassive bleeding, one case
of cardiac arrhythmia and one case of pneumonia. No
procedure-related mortality occurred.
DISCUSSION
The effectivity rate ofNd-YAG laser treatment for tra-
cheobronchial obstruction by malignant tumor is
around 42.7 to 84.4% [4,5]. It is mainly determined by
the following factors: criteria of patient selection,
experience of the bronchoscopist, type of broncho-
scope used, and type of anaesthesia. A rather aggres-
sive attitude with employment of rigid bronchoscope
with good coordination between the bronchoscopist
and anaesthesiologist would probably have yielded a
higher effectivity rate with lesser complications.
Usage of the flexible bronchoscope and local anaes-
thesia, as in our patient group had some shortcomings.
Patient cooperation was extremely vital and results
varied subjectively. The short anaesthesia duration
posed another problem. In addition, evacuation of
necrotic tissues was often incomplete, bleeding con-
trol inadequate and control of ventilation was difficult
and far from ideal. These could have accounted for a
rather low (39.4%) effectivity rate of Nd-YAG laser
treatment of airway obstruction, due to malignant
tumor. We had one case of intraluminal carcinoid of
low grade malignancy with complete cure by laser
treatment alone and had no evidence of recurrence up
to 5 years follow-up. The effectivity rate of Nd-YAG
laser treatment for tracheobronchial obstruction by
benign lesions is usually better than that caused by
malignant tumor. In our series, the effectivity rate was
81.3% for benign lesions compared to 39.4% for
malignant tumor. Although there were some advan-
tages of contact Nd-YAG laser than the non-contact
type, the effectivity rates for both types of Nd-YAG
lasers were not significantly different (p > 0.4). The
small sample size in this series could have made this
finding weak. No comparison of side effects was made
in this study. If there was, there would be expectedly,
lesser complication with the contact type Nd-YAG
laser. We had 3 cases with major complications and no
procedure-related mortality. Reported incidences of
morbidity in the literature ranged from 1.8 to 2.3%,
and the mortality rate was 0.4 to 1.2% [4-11].
TABLE III Effectivity rate ofND-.YAG laser treatment according to diagnosis type
Diagnosis Patient no. C.E. (%) P.E. % Overall (%)
Benign 32 40.6 40.6 81.3"
Malignant 33 3.1 36.3 39.4"
Total 65 21.5 38.5 60.0
*p < 0.005, C.E. complete effect, P.E. partial effect
TABLE IV Effectivity rate ofNd-YAG laser treatment according to laser type
Diagnosis Patient no. C.E. (%) P.E. (%) Overall (%)
Non-contact 48 25.0 37.5 62.5"
Contact 17 11.7 41.1 52.9"
Total 65 21.5 38.5 60.0
*p > 0.4, C.E. complete effect, P.E. partial effect110 R. PERNG et al.
Due to its low morbidity and mortality rates, the
Nd-YAG laser remained a safe and effective treatment
modality and is specifically recommended for lesions
causing tracheobronchial obstruction.
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